The severity of vascular inflammation and its relationship with clinical and functional features in patients with chronic obstructive pulmonary disease without concomitant cardiovascular pathology
- Authors: Tayutina T.1, Klimenko N.1, Kudlay D.2,3,4, Shovkun L.1, Nikolenko N.5
-
Affiliations:
- Rostov State Medical University, Ministry of Health of Russia
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- M.V. Lomonosov Moscow State University
- National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
- The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
- Issue: Vol 35, No 2 (2024)
- Pages: 24-30
- Section: For Diagnosis
- URL: https://journals.rcsi.science/0236-3054/article/view/257843
- DOI: https://doi.org/10.29296/25877305-2024-02-05
- ID: 257843
Cite item
Open Access
Access granted
Subscription Access
Abstract
The Russian Federation is one of the countries with a high prevalence of chronic obstructive pulmonary disease (COPD). In the last decade, the list of families of chemical regulators of vascular inflammation in COPD has been supplemented with information about growth factors, whose participation in the processes of regulation of vascular function seems significant. The study of the role of angiogenesis factors in patients with isolated COPD disease is insufficient at this stage and needs to be clarified.
Objective. To study was to identify diagnostic and prognostic criteria for the severity of vascular inflammation and to assess its relationship with clinical and functional features in patients with COPD without concomitant cardiovascular pathology in comparison with the clinical phenotype of the disease.
Material and methods. 96 patients with COPD were examined, the median age was 61 years. In addition to standard clinical, functional and laboratory research methods, the severity of vascular inflammation was assessed in all examined patients with the determination of quantitative indicators of human platelet growth AA factor and tumor necrosis factor-α (TNFα) by quantitative solid-phase enzyme immunoassay
Results. In all patients with isolated COPD, regardless of the risk of developing the underlying disease, an increase in the level of platelet growth AA factor and TNFα was noted. The level of platelet growth AA factor and TNFα in patients with COPD, regardless of the risk of exacerbation, was correlated with the functional state of the lungs, clinical phenotype and severity of clinical manifestations of the disease. The value of platelet growth AA factor above 317 ng/ml in patients with COPD may be an early marker of endothelial dysfunction and a predictor of the development of hemostatic disorders and concomitant cardiovascular pathology.
Full Text
##article.viewOnOriginalSite##About the authors
T. Tayutina
Rostov State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: tarus76@mail.ru
Candidate of Medical Sciences, Associate Professor
Russian Federation, Rostov-on-DonN. Klimenko
Rostov State Medical University, Ministry of Health of Russia
Email: tarus76@mail.ru
Candidate of Medical Sciences
Russian Federation, Rostov-on-DonD. Kudlay
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); M.V. Lomonosov Moscow State University; National Research Center – Institute of Immunology Federal Medical-Biological Agency of Russia
Email: tarus76@mail.ru
MD, Corresponding Member of the Russian Academy of Sciences, Professor
Russian Federation, Moscow; Moscow; MoscowL. Shovkun
Rostov State Medical University, Ministry of Health of Russia
Email: tarus76@mail.ru
MD, Professor
Russian Federation, Rostov-on-DonN. Nikolenko
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Email: tarus76@mail.ru
Candidate of Pharmaceutical Sciences
Russian Federation, MoscowReferences
- Andreeva E., Pokhaznikova M., Lebedev A. et al. The prevalence of chronic obstructive pulmonary disease by the Global Lung Initiative equations in North-Western Russia. Respiration. 2016; 91 (1): 43–55. doi: 10.1159/000442887
- Архипов В.В., Архипова Д.Е., Стукалина Е.Ю. и др. Частота встречаемости отдельных фенотипов хронической обструктивной болезни легких в Российской Федерации, их характеристики и подходы к лечению. Практическая пульмонология. 2016; (3): 20–5 [Arkhipov V.V., Arkhipova D.E., Stukalina E.Yu. et al. COPD Phenotypes in Russia: Characteristics and Treatment. Practical pulmonology. 2016; (3): 20–5 (in Russ.)].
- Драпкина О.М., Концевая А.В., Муканеева Д.К. и др. Прогноз социально-экономического бремени хронической обструктивной болезни легких в Российской Федерации в 2022 году. Пульмонология. 2022; 32 (4): 507–16 [Drapkina O.M., Kontsevaya A.V., Mukaneeva D.K., et al. Forecast of the socioeconomic burden of COPD in the Russian Federation in 2022. Pulmonologiya. 2022; 32 (4): 507–16 (in Russ.)]. doi: 10.18093/0869-0189-2022-32-4-507-516
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023. URL: https://goldcopd.org/
- Шолкова М.В., Доценко Э.А. Эндотелиальная дисфункция при хронических обструктивных заболеваниях легких. Неотложная кардиология и кардиоваскулярные риски. 2019; 3 (1): 539–45 [Sholkava M.V., Dotsenko E.A. endothelial dysfunction in chronic obstructive pulmonary diseases. Emergency cardiology and cardiovascular risks. 2019; 3 (1): 539–45 (in Russ.)].
- Heodorakopoulou M.P., Alexandrou M.E., Bakaloudi D.R. et al. Endothelial dysfunction in COPD: a systematic review and meta-analysis of studies using different functional assessment methods. ERJ Open Res. 2021; 7 (2): 00983-2020. doi: 10.1183/23120541.00983-2020
- Хасанов А.Х., Бакиров Б.А., Давлетшин Р.А. и др. Лабораторный скрининг дислипидемии, апоптоза, оксидативного стресса у пациентов с мультифокальным атеросклерозом средней возрастной категории с феноменом «преждевременного старения». Терапия. 2019; 4 (30): 49–56 [Khasanov A.Kh., Bakirov B.A., Davletshin R.A. et al. Laboratory screening of dyslipidemia, apoptosis, oxidative stress in patients multifocal atherosclerosis middle age category with the phenomenon of «premature aging». Therapy. 2019; 4 (30): 49–56 (in Russ.)]. doi: 10.18565/therapy.2019.4.49-56
- Самойлова Ю.Г., Матвеева М.В., Петров И.А. и др. Оксидативный стресс и фертильность. Природа, диагностика, терапия. Вопросы гинекологии, акушерства и перинатологии. 2021; 20 (4): 131–9 [Samoilova Yu.G., Matveeva M.V., Petrov I.A. et al. Oxidative stress and fertility. Nature, diagnosis, and treatment. Gynecology, Obstetrics and Perinatology. 2021; 20 (4): 131–9 (in Russ.)]. doi: 10.20953/1726-1678-2021-4-131-139
- Шовкун Л.А., Кудлай Д.А., Николенко Н.Ю. и др. Характеристики некоторых препаратов с антиоксидантной активностью и их применение для лечения туберкулеза. Туберкулез и болезни легких. 2020; 98 (4): 58–64 [Shovkun L.A., Kudlay D.A., Nikolenko N.Yu. et al. Characteristics of certain drugs with antioxidant activity and their use in tuberculosis treatment. Tuberculosis and Lung Diseases. 2020; 98 (4): 58–64 (in Russ.)]. doi: 10.21292/2075-1230-2020-98-4-58-64
- Юдина Н.Ю., Назаркина И.М., Кудлай Д.А. Оксидантно-антиоксидантная система эритроцитов при хронической обструктивной болезни легких. В сб.: ГБУЗ СО «Самарская городская клиническая поликлиника №15» г.о. Самара: 70 лет созидания и развития – к новым достижениям. Сб. науч. работ научно-практ. конф. Под ред. Т.А. Лариной, И.М. Назаркиной. Самара, 2018; с. 532–4 [Yudina N.Yu., Nazarkina I.M., Kudlai D.A. Oksidantno-antioksidantnaya sistema eritrotsitov pri khronicheskoi obstruktivnoi bolezni legkikh. V sb.: GBUZ SO «Samarskaya gorodskaya klinicheskaya poliklinika №15» g.o. Samara: 70 let sozidaniya i razvitiya – k novym dostizheniyam. Sb. nauch. rabot nauchno-prakt. konf. Pod red. T.A. Larinoi, I.M. Nazarkinoi. Samara, 2018; рр. 532–4 (in Russ.)].
- Шабанов П.Д., Ганапольский В.П., Жумашева А.Б. и др. Трекрезан как метаболический активатор, обладающий свойствами метеоадаптогена, психоэнергизатора и иммуномодулятора. Вестник Российской военно-медицинской академии. 2006; 15 (1): 53–7 [Shabanov P.D., Ganapol'skii V.P., Zhumasheva A.B. et al. Trekrezan kak metabolicheskii aktivator, obladayushchii svoistvami meteoadaptogena, psikhoenergizatora i immunomodulyatora. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2006; 15 (1): 53–7 (in Russ.)].
- Таютина Т.В., Клименко Н.Ю., Лысенко А.В. и др. Особенности функционального состояния эндотелия и гемодинамики левого желудочка при прогрессировании хронического легочного сердца у больных с хронической обструктивной болезнью легких. Медицина: теория и практика. 2023; 8 (3): 26–35 [Tayutina T.V., Klimenko N.Yu., Lysenko A.V. et al. Features of the functional state of the endothelium and hemodynamics of the left ventricle in the progression of chronic pulmonary heart in patients with chronic obstructive pulmonary disease. Medicine: theory and practice (St. Petersburg). 2023; 8 (3): 26–35 (in Russ.)]. doi: 10.56871/MTP.2023.78.91.003
Supplementary files
